Patels and Company Capital

Pankaj Patel, chairman of Zydus Lifesciences, serves as the principal decision-maker. The office operates with a lean structure typical of founder-led Indian family offices — investment recommendations are sourced through a small internal team and Patel's professional network, with final sign-off resting with the family principal. Publicly, no separate CEO or CIO has been named for the family office entity.

Patels and Company Capital is the private investment vehicle of the Patel family, who control Zydus Lifesciences (formerly Cadila Healthcare), a publicly traded pharmaceutical company. The family office sits outside the listed entity and invests family wealth independently, though it leverages the domain expertise and network built through Zydus. The two entities are legally separate, with the family office not holding an operational role in the public company beyond the family's board-level governance.

The office targets a mix of early-stage venture, growth equity, and opportunistic real assets. In venture, it has participated in Series A and B rounds for health-tech and AI-driven diagnostics companies. Real estate investments concentrate on income-generating commercial properties, while the credit sleeve appears focused on performing-credit fund commitments rather than distressed or special-situations lending.

Patels and Company Capital uses a hybrid model: it writes direct checks into startups, particularly those operating at the intersection of healthcare and technology, while also acting as a limited partner in Indian and global VC and private-credit funds. The fund-commitment activity suggests an intent to access deal flow and manager expertise in sectors beyond the family's core pharmaceutical competency.

The wealth originates from Cadila Healthcare, founded in 1952 by Ramanbhai Patel, Pankaj Patel's father. The company grew into one of India's largest pharmaceutical manufacturers under the Zydus brand, with a portfolio spanning generics, active pharmaceutical ingredients, biosimilars, and consumer health products. Pankaj Patel scaled the business into a publicly traded global enterprise, generating the liquidity the family office now manages.